Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat maintenance after autologous stem cell transplant in high-risk classical Hodgkin lymphoma
NL-OMON36301Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in classical Hodgkin lymphoma (cHL) comparing Panobinostat maintenance with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Jan 2011; status: active, not recruiting.
02
Drugs
panobinostat
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON36301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36301.